BeiGene, Ltd.
BGNE
Rank in Stocks
#1194
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$184.00
Last synced: 2025-01-02
Market Cap
$19.28B
Change (1 day)
-0.38%
Change (1 year)
0.00%
Country
US
Trade BeiGene, Ltd. (BGNE)
Category
Healthcare
Revenue for BeiGene, Ltd. (BGNE)
Revenue in Jun 2026 TTM: $6.13B
According to BeiGene, Ltd. latest financial reports the company's current revenue (TTM) is $6.13B. In 2023 the company made a revenue of $2.46B an increase over the revenue in the year 2022 that was $1.42B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BeiGene, Ltd. from 2013 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $6.13B | 60.85% |
| 2024 | $3.81B | 54.96% |
| 2023 | $2.46B | 73.65% |
| 2022 | $1.42B | 20.37% |
| 2021 | $1.18B | 280.83% |
| 2020 | $308.87M | -27.87% |
| 2019 | $428.21M | 116.03% |
| 2018 | $198.22M | -16.85% |
| 2017 | $238.39M | 22,179.16% |
| 2016 | $1.07M | -87.86% |
| 2015 | $8.82M | -32.37% |
| 2014 | $13.04M | 16.93% |
| 2013 | $11.15M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 105.98% |
US
|
|
| $2.23B | -63.65% |
US
|
|
| $15.74B | 156.88% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | -1.76% |
NL
|
